In clinical oncology and health equity research, the systematic absence of gender-identity data collection in routine clinical practice and cooperative-group research databases constitutes a structural data gap that prevents identification of transgender patients within a disease population, which in turn precludes downstream analysis of health disparities, treatment safety (e.g., continuation of hormone therapy during treatments such as allogeneic stem cell transplantation), and care-coordination questions (e.g., timing of transition-related procedures relative to treatment). The underlying principle is that demographic subgroup analysis and disparities research are contingent on prior, deliberate identity-data collection; absent that collection, an entire class of clinical and health-equity questions becomes unanswerable regardless of study design.
In clinical oncology and health equity research, the systematic absence of gender-identity data collection in routine clinical practice and cooperative-group research databases constitutes a structur…